Effect of roxadustat on renal anemia in hemodialysis patients
Not Applicable
- Conditions
- End-stage renal disease
- Registration Number
- JPRN-UMIN000039598
- Lead Sponsor
- Saitama Tsukinomori Clinic
- Brief Summary
Roxadustat (median 100 mg/HD) could maintain Hb in dialysis patients treated with high-dose darbepoetin (mean dose 54 maicrogram/wk) for 1 year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin concentration, serum iron, transferrin saturation, serum ferritin, hepcidin
- Secondary Outcome Measures
Name Time Method